Clinical Trial Update: Sage Therapeutics

Sage Therapeutics Discontinue Dalzanemdor Trial

We are saddened to share that the clinical trial for dalzanemdor, a drug aimed at improving cognitive challenges for people with Huntington’s disease, has been discontinued. Unfortunately, the results did not show significant differences compared to a placebo. For more details, you can read the full article on HD Buzz linked below.

While this news is disappointing, we remain hopeful and committed to supporting research and advancements in treatments for the HD community. Visit our Research Updates section to explore other developments in this space.

If you have any questions or need support, please don’t hesitate to reach out to us at Huntington’s Victoria.